Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
Shares of weight-loss drugmakers including Eli Lilly & Co., Novo Nordisk A/S and Structure Therapeutics Inc. fell on Wednesday after Roche Holding AG announced positive early-stage trial data for its experimental obesity pill.
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, Altimmune (NASDAQ:ALT) shareholders have done very
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating
B.Riley Financial analyst Mayank Mamtani maintains $Altimmune(ALT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -16.5% over
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
Better GLP-1 Biotech Stock: Altimmune Vs. Viking Therapeutics
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
Altimmune to Participate at Leerink Partners Therapeutics Forum
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Express News | Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic
Express News | Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's chief financial officer. What To Know: Eisenstadt'
Altimmune Drops 15% After Sudden Death of Finance Chief
By Victor Swezey Shares of Altimmune fell Wednesday after Chief Financial Officer Richard Eisenstadt died suddenly. In afternoon trading, the stock was down 15% to $6.31. Shares are still up 83% in
Express News | Altimmune Shares Are Trading Lower Following the Passing of CEO Richard Eisenstadt
Express News | Altimmune Shares Down 9% at $6.7 After Co Announces Passing of CFO
Altimmune Initiates Search For New CFO - Quick Facts
Express News | Altimmune Inc: On June 25, Appointed Andrew Shutterly as Acting Chief Financial Officer
Express News | Altimmune Announces Passing Of Chief Financial Officer, Richard Eisenstadt; Eisenstadt's Duties Are Being Assumed And Performed Bt Finance And Accounting Team Until Replacement Is Named